Keith Gottesdiener, M.D., is the President and Chief Executive Officer of PRIME Medicine, Inc., a biotechnology company focused on developing novel gene editing therapies. Dr. Gottesdiener brings extensive experience in the biopharmaceutical industry, having previously served as the President and CEO of Rhythm Pharmaceuticals, where he successfully led the company through the development and regulatory approval of its first product, IMCIVREE, for the treatment of obesity and hyperphagia in patients with specific genetic disorders. Prior to his role at Rhythm Pharmaceuticals, Dr. Gottesdiener spent nearly two decades at Merck & Co., where he held various leadership positions, including Vice President and Head of Late-Stage Development for Diabetes and Endocrinology, and Senior Vice President and Head of Global Clinical Development. During his tenure at Merck, he played a key role in the development and approval of several blockbuster drugs, including JANUVIA for type 2 diabetes and ISENTRESS for HIV. As the President and CEO of PRIME Medicine, Dr. Gottesdiener is responsible for guiding the company's strategic direction and overseeing the development of its innovative Prime Editing platform, which has the potential to precisely correct a wide range of genetic mutations. His leadership and deep understanding of drug development and regulatory processes are invaluable assets as PRIME Medicine works to bring transformative therapies to patients with genetic diseases.